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The experiments described  in  this  paper are  concerned  with  the  mechanism  by 
which  major  histocompatibility  antigens  delivered  on  allogeneic  cells  induce  an 
antibody response in vivo. The matter is of some interest in view of the characteristic 
anomalies associated with alloreactivity in general. Does the response of an appropri- 
ately immunized animal reflect the outcome of an alloreaction, or of a  conventional 
immune response in which  alloreactivity plays no significant part? The issue hinges 
on the nature and specificity of help provided to the B cell precursors of alloantibody- 
forming cells. Do helper cells exist for alloantibody production in vivo, and if they do, 
are they specific for the immunizing alloantigen alone, for the immunizing alloantigen 
restricted by the I  region products of the donor, or for the  immunizing alloantigen 
restricted by the I region products of the responder? Only in the last case would one 
describe the cellular mechanism of the alloantibody response as conventional. 
Our experiments show that the last case provides the best description of the in vivo 
antibody response of rats to the RT1A-region  specific (class I, mouse H-2K/D-like) 
alloantigens, and we therefore conclude that for practical purposes, the alloantibody 
response is indeed largely, if not entirely, conventional in mechanism. This analysis is 
based on  the  discovery and  properties of potent  major histocompatibility complex 
(MHC)Llinked immune response (It) genes governing the response of the alloantigen 
immunized recipient.  There is  a  precedent  for such  Ir  genes  in  the early studies  of 
Stimpfling and  Durham  (1)  and  Dorf and  Stimpfling  (2)  on  the  response  of B10 
congenic mice to the H-2D  b private specificity H-2.2.  Our own studies confirm the 
existence of such Ir genes and extend  the  findings  to demonstrate that  the level of 
responsiveness  of the  recipient  is  largely  independent  of  the  form  in  which  the 
immunizing alloantigen  is delivered.  We further demonstrate  that  the  responses to 
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two epitopes on  the  same alloantigenic  molecule are controlled  concordantly,  and 
that low-responder B cells are normally unable to participate in the antibody response. 
To account  for our findings, we locate the/r  gene effect to the helper mode of the 
immune response, and suppose that major alloantigens delivered on viable cells must 
normally be reprocessed by host antigen-presentation systems before the induction of 
helper cells. 
Materials and Methods 
Animals.  The rat strains used and their MHC  haplotypes are listed in Table I. All the rats 
used were bred in our department  (lap sublines). The PVG-congenic series is described in a 
communication to the Rat News Letter (4).  The  properties of the A  and  B  regions of the rat 
MHC have been described elsewhere (5-11). Briefly, the A region specifies class I alloantigenic 
molecules and the B  region specifies mouse H-2Ia-like molecules and functions. 
Immunizations.  For the production ofalloantisera, animals were immunized by subcutaneous 
(s.c.)  and intraperitoneal  (i.p.)  routes.  1 ml of a  suspension of pooled spleen and lymph node 
cells in either Dulbecco's phosphate-buffered saline (PBS) with no added serum or Dulbecco's 
A  and B salts solution containing 2% fetal calf serum  (DAB/FCS) was distributed among five 
s.c.  sites  (2  ×  0.1  ml  to  shoulders  and  flanks,  and  0.1  ml  to  the  base  of the  tail)  and  the 
peritoneal cavity (0.5 ml). For the demonstration of secondary allo-plaque-forming cells (allo- 
PFC) against RT1A" (Table IV),  1 ml of a  similar cell suspension was injected into the lateral 
tail vein. The doses of cells used for immunization were normally in the range of 12-50 ×  106 
pooled  spleen  and  lymph  node cells  (1A2-1~ donor equivalents)  per recipient.  There  was  no 
noticeable effect of dose over this range. Further details of immunization protocols are given in 
TABLE  I 
Rat Strains  Used* 
Strain 
MHC haplotype 
A region  B region 
AGUS 
AO 
AUG 
DA 
PVG (previously also called HO) 
MHC congenic strains on the PVG background 
PVG-RTI" (DA)  N6F >  2 
PVG-RTI  t (AGUS)  N9F >  2 
HO.B2 (AO):[:  N7F >  2 
PVG-RT1  ~ (AO)  N7F?N6F >  2 
l  l 
u  u 
c  c 
a  a 
c  C 
a  a 
l  l 
u  u 
u  u 
MHC recombinants 
PVG.R 1 (congenic)  NSF6F >  2  a  c haplotype name rl 
RS§  a  u haplotype name r8 
* All  the rat strains described here except  the R8  line are available from  OLAC  Ltd.,  Shaw's Farm, 
Blackthorn, Bicester, Oxon, Eng. 
$ The HO.B2 congenic strain was derived by Ford and Simmonds (3). It was further backcrossed on to the 
PVG background in our laboratory and the resulting line was renamed PVG-RTI  u (AO).  Throughout 
the text, HO.B2 and PVG-RTI" rats will  not be distinguished and will all be referred to by the latter 
name. 
§ The recombinant haplotype r8 was recently discovered in a  (DA ×  AO)F2  population. The rat bearing 
it was crossed  to PVG. A line homozygous for r8 was extracted from the progeny of this cross  by full 
sibling mating with appropriate selection.  Thus, the rat stock R8 is undoubtedly heterozygous at many 
loci outside the MHC. BUTCHER,  CORVAL/i,N, LICENCE, AND HOWARD  305 
figure and table legends. A single exception to the range of immunizing  doses described above 
was in the secondary intravenous (i.v.) immunization of the PVG +  PVG-RT1 u ~  (PVG × 
PVG-RTIU)FI chimeras (Table V), where a dose of only 106 spleen and lymph node cells was 
used. Rats were bled either by cardiac puncture or from the tail 7-11 d after immunization.  All 
antisera were inactivated by heating at 56°C for 30 min and were stored at -20°C. 
Preparation of Heat-killed Homogenized Cells.  Suspensions of pooled spleen and lymph node 
cells in PBS  were  incubated for 30 min at 56°C. At this stage,  the viability of the cells was 
assessed by Trypan Blue dye exclusion: 100% of cells examined took up the dye over a  10-min 
period of observation. Subsequently, the cell  population was homogenized for 2 min on ice 
using a Polytron Homogenizer (Kinematica GMBH, Luzerne, Switzerland) at setting 4. 
Complement-dependent Lymphocytotoxicity Tests.  These were conducted essentially as described 
previously (8)  except  that  V-bottomed microtiter plates  (M25A;  Sterilin Ltd.,  Teddington, 
Middlesex, Eng.)  were  used.  In some cases,  the  assay  was  adapted  to  accommodate serial 
threefold dilution series of antiserum. Freshly prepared lymph node cells, depleted of dead cells 
by centrifugation over Ficoll-Isopaque solution (12) were labeled with Na2~lCrO4 and used as 
target cells (2.5 ×  104 per well of microtiter plate). Titers were defined as the concentration at 
which the antiserum released one-half of the SXCr counts released at  the cytotoxic plateau. 
Spontaneous release  of label in the absence of serum was  always <12%  of the  total  input 
whereas plateau releases were always >60% of total input. 
Monoclonal Antibodies Against Defined Determinants of RTIA a.  The four monoclonal antibodies 
R2/10P, R2/15S, R3/13, and R3/47 have been described in detail elsewhere  (13-16). R2/10P 
and R3/13 define the P epitope, and R2/15S and R3/47 the S epitope of RT1A  a molecules. 
All molecules carrying the P epitope also carry the S epitope, and antibodies binding  to the two 
determinants are noncompetitive. Some of the monoclonal antibody supernatants used con- 
tained mouse immunoglobulin (Ig) chains derived from the parent mouse myeloma X63. To 
indicate the chain composition of the supernatants used here, the letters H  and L denote the 
rat-derived heavy and light immunoglobulin  chains, G and K  the X63-derived mouse heavy 
and  light  Ig  chains.  Monoclonal antibodies  internally labeled  with  [3H]lysine  have  been 
described elsewhere  (17). 
Hemolytic Plaque Assays for Allo-PFC.  The principle of this assay has been described in a 
recent publication (18). Donors were immunized intravenously  with alloantigen-bearing  viable 
lymphocytes. Spleen cells were taken 7 d after immunization (see above), washed in DAB/FCS, 
and diluted in an appropriate volume of DAB/FCS. Cunningham plaque chambers were filled 
with a mixture containing 100 p.1 spleen cell suspension, 2 drops of RPMI 1640 medium, 1 drop 
of monoclonal antibody directed against the P  (R2/10P, R3/13) or S (R3/47) epitopes of the 
RT1A" molecule, 1 drop of DA erythrocytes (RBC), and 2 drops of guinea pig serum absorbed 
with rat RBC (two parts guinea pig serum to one part packed rat RBC) used at a concentration 
(from x/2 to ah depending on batch) at which nonspecific lysis of the RBC layer was undetectable. 
The drops were delivered from a 23-gauge hypodermic needle from which the bevel had been 
removed. Chambers were incubated for ~ 1 h at 37°C and plaques were read by eye without 
magnification. 
Hemolytic Plaque Assay for  Anti-Sheep  RBC  (SRBC)  Antibody-forming Cells.  The  assay  was 
performed as described for  allo-PFC except  that  the monoclonal antibody was  replaced by 
RPMI 1640 and the guinea-pig serum was absorbed at a ratio of four parts serum to one part 
packed SRBC. 
Competitive Inhibition by Antiserum of the Binding of Internally Radiolabeled Monoclonal Alloantibodies 
to RBC Targets.  2.5  ×  10  ~ strain DA RBC, were incubated at  4°C with serial dilutions of 
antiserum or normal serum in a total volume of 0.05 ml in V-bottomed microtiter trays. Trays 
were shaken periodically. After 1 h, 0.025 ml of an appropriate dilution of culture supernatant 
containing monoclonal anti-RT1A" antibody internally labeled with [3H]-L-lysine ([aH]Lys) 
was  added to each well.  The plates were incubated at 4°C for a  further 60 min. The RBC 
pellets  were  washed  three  times  with  0.2  ml  DAB/FCS,  collected  with  a  semiautomatic 
harvester (Otto Hiller, Madison, Wise.)  using a  saline wash on to glass-fiber filters (GF/A; 
Whatman Biochemicals Ltd.,  Maidstone, Kent, England), and counted in a  fl-scintillation 
spectrometer (Packard Tri-carb 3255, Packard Instrument Co., Inc., Downers Grove, Ill.). The 306  /r GENE CONTROL  OF RESPONSES TO ALLOANTIGENS 
[3H]Lys-labeled  antibody-containing  supernatants used were  R2/15S.HL and R3/13.HLGK 
prediluted in DAB/FCS to 1/500 and 1/30, respectively, relative to original supernatant. 
Radiation Chimeras.  (PVG X PVG-RTlU)F1 ft recipients (10-12 wk old)  were given a  total 
mid-body dose of 900-rad  16-MeV x rays from an electron linear accelerator at New Adden- 
brookes  Hospital,  Cambridge,  England (MEC  SL75/20;  Phillips Group;  Amsterdam, The 
Netherlands). Within 4 h of irradiation, recipients were given an i.v. injection of fetal liver cells 
pooled from embryos at  14-18 d gestation in 1 ml DAB/FCS. Viable cells were not counted, 
but the injected dose of cells was equivalent to  1-2 embryos per recipient. In the experiments 
described, Fi recipients received either PVG, PVG-RTI", or an equal mixture of the two fetal 
liver suspensions. The three classes of chimeras are referred to in the text as c ~  (c X u)Fi u 
(c X u)Fi and c +  u --~ (c X u)Fl, respectively, where c and u refer to the RT1 haplotypes. 
All chimeras were  immunized with  1 ml  1%  SRBC  i.v.  at  ~6 wk  after reconstitution to 
demonstrate restoration of T  cell  function (19). The chimeric status  of most  animals was 
demonstrated by appropriate cytotoxic alloantisera on peripheral blood lymphocytes before use 
(Fig.  5)  or on spleen lymphocytes at  the time of assay (Table V).  In no case could cells of 
recipient origin be detected (< 10%). In the c +  u ~  (c x  u) chimeras, the level ofreconstitution 
with the two parental populations was approximately equal. 
Assays  of  Origin  of  Plaque-forming Cells  (PFC)  in  Radiation  Chimeras  Using Cytotoxic 
Alloantisera.  The origin of alIo-PFC and anti-SRBC PFC in c  +  u ~  (c  X  u) chimeras was 
demonstrated  by  elimination of PFC  with  specific  cytotoxic  alloantisera and  complement 
essentially as described elsewhere  (20, 21). As a control for nonspecific loss of PFC, suspensions 
were also  incubated with normal type AO serum instead of antiserum. To eliminate PFC of 
RTI  c origin, the antiserum S.245 (AO ×  PVG.RTI")F1 anti-PVG was used; to eliminate PFC 
of RTl" origin, the antiserum S.207 (AGUS X PVG)F1 anti-PVG-RTI" was used. In one group, 
a mixture of the two antisera was used.  In all cases, the final concentration of each antiserum 
in  the  incubation mixture was  1/36.  At  this  concentration, the  anti-RTf  antiserum had 
previously been shown to eliminate 98% of alIo-PFC of (c  X  u) origin whereas the anti-RTl" 
antiserum eliminated 93%, compared with normal AO serum controls. After incubation with 
antiserum and complement, suspensions were washed and resuspended to their original volumes. 
Aliquots were  then  assayed  for  PFC  against  DA  RBC  and  SRBC.  Data  are  expressed  in 
PFC/spleen derived from each suspension after serum treatment. 
Results 
General Features of the  Immune  Response to  RT1A a and  RT1A  c.  Our  attention was 
drawn to the possibility that antibody responses to MHC alloantigens in the rat were 
significantly influenced by  dominant genetic factors  in the  responder by the  large 
difference in the  primary and secondary anti-RT1  a lymphocytotoxic antibody titer 
between  PVG(RTI  c)  rats  and  (AO  X  PVG)F1  hybrids  (RTI~/RTF)  immunized 
against DA(RT1 a) lymphoid cells (Fig. 1 A and B). Since RT1B antigens (class II) are 
present on only a  subpopulation of peripheral lymphocytes (5, 9),  it was likely that 
the  greater  part  of the  difference  in  titer  was  in  the  response  to  RT1A  a  antigens 
(class I). 
The relatively feeble response of the low-responder strain PVG to RT1A  a antigens 
was  still more reduced  if recipients were  immunized with  PVG.R1  (RT1AalT)  (see 
Table I)  instead of DA(RT1AaB  ~)  lymphoid cells (Fig.  1 C  and D). We attribute the 
difference  in  response  to  RT1A"  antigens with  these  two  different  immunogens 
primarily to elimination of allogeneic effects because of the RT1B-region incompati- 
bility  associated  with  the  DA  cells.  Incompatibility at  non-MHC  loci  may  also 
contribute to the greater response against RT1A  ~ delivered on DA cells (e.g., "inter- 
molecular help"  [22]).  Certainly, the  response of PVG  against  PVG.R1  is  always 
small, whereas that of PVG to DA or to PVG-RTI" can vary greatly depending on 
the  means and  frequency of immunization. Thus,  antisera obtained from  animals BUTCHER,  CORVAL,~N, LICENCE, AND HOWARD 
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FIG.  1.  The antibody response to RTI  a antigens. Influence of responder genotype, immunogen 
genotype and immunization protocol. (A and B) Four PVG rats (--) and four (AO × PVG)FI rats 
(0) were immunized against DA on days 0 and 32. They were bled on day 7 (A, primary response) 
and day 39 (B, secondary response), and the sera assayed against PVG-RTI" lymph node cells. (C 
and D) The sera from the four PVG rats immunized against DA (A and B) were reassayed against 
PVG.R1 lymph node targets (--), and compared with sera from three PVG rats immunized against 
(PVG.Rt  ×  PVG)F1 on days 0 and 39 and bled on days  11  and 48  (---). (×)  Titration of an 
antiserum obtained from a single PVG immunized against DA on days 0 and 247 and bled on day 
25'(. Immunizations and complement-dependent lymphocytotoxic assays on ~=Cr-labeled targets 
were conducted as described in Materials and Methods. The final concentration of antiserum in the 
first well of each titration was 1:6. 
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primed with a  skin graft  can be very strong in these combinations, but not in the 
combination PVG anti-PVG.R1. One high-titered PVG anti-DA serum is illustrated 
in Fig.  1 D. This was obtained from an animal left unimmunized for 254 d  between 
its priming and boosting injections of lymphocytes. Such anti-RT1A  a responses from 
PVG rats immunized against DA or PVG-RT1 a rule out the possibility that PVG rats 
lack B cells specific for determinants of the RT1A  a molecules. 
Because the difference between high and low responders to  RT1A  ~ was  greatest 
after immunization  with PVG.R1 cells, these cells were used as the immunogen in the 
genetic analysis of responsiveness that  follows. Appropriate controls for differential 
allogeneic effects in low- and high-responder recipients of PVG.R 1 cells are included 
in a  later section of this paper. 
Differential responsiveness to the RT1A  c antigens of PVG was seen by immunizing 
low-responding PVG.R1  (RTIAaff)  or high-responding (PVG.R1  ×  PVG-RTlU)Fx 
recipients  with  PVG  lymphoid cells.  This  comparison  was  more  impressive  than 
between DA  (low)  and  (AO  ×  DA)F1  (high)  responding to  the same immunogen, 
presumably again on  account of the elimination of RT1Boregion  allogeneic effects 
and background incompatibilities in the low-responder combination. 
Genetics  of Responses  to  RT1A ~ and RT1A ~.  19  (AO  ×  PVG)F1  ×  PVG backcross 
progeny  were  immunized against  RT1A  ~.  The  responses  (Fig.  2A)  fell  into  two 
nonoverlapping groups in both primary and secondary responses:  typing for RTI ~, 308  Ir  GENE  CONTROL  OF  RESPONSES  TO  ALLOANTIGENS 
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FIG.  2.  The  genetics  of responsiveness  to  RTIA".  Accumulated  data of primary  and  secondary 
]ymphocytoto×ic  titers of rats  of various  genotypes  immunized  against  (PVG  x  PVG.RI)F~  or 
PVG.R1. All immunizations were congenic, the only disparity between responder and immunogen 
being the RT1A = region. Each symbol represents the response of one animal 
Responder  Symbol  Genotype  Immunogen 
Panel A 
PVG  X  c/c  rl/c 
(AUG X PVG)F1  +  c/c  rl/c 
(AO X PVG)F1  •  u/c  rile 
(AO X PVG)FI  x  PVG backcross progeny  Q)  c/c  rl/c 
(AO X PVG)FI  x  PVG backcross progeny  •  u/c  rl/c 
(PVG X PVG-RTfl  ~) X PVG backcross progeny (N12)  []  c/c  rl/c 
(PVG X PVG-RTfl') ×  PVG backcross progeny (N12)  •  u/c  rl/c 
PVG-RTlU/RT1C (N7)  •  u/c  rl/c 
Panel B 
Primary response 
(PVG-RTI  t X PVG)FI  ×  PVG backcross progeny  <>  c/c  rl/c 
(PVG-RTI  t X PVG)F1  ×  PVG backcross progeny  •  l/c  rl/c 
Secondary response: 
(PVG-RTI  1 ×  PVG)F1  X PVG backcross progeny  0  c/c  rl/rl 
(PVG-RTI  t )4  PVG)FI  ×  PVG backcross progeny (a different  •  lie  rl/rl 
litter from primary response) 
(AO ×  PVG)F1  •  u/c  rl/rl 
Secondary  immunizations were  performed  between  29  and  39  d  after  the  primary.  Bleeds were  taken 
between  7 and  11  d  after immunization. All antisera were  titrated  against  lymph node ceils from  DA 
donors. The symbols >  and <  indicate that the titer of the antiserum was greater than, or less than, that 
plotted. See Materials and Methods for definition of titer in these assays. 
the segregating MHC of AO origin, revealed that all members of the high-responding 
group carried this haplotype,  whereas all  low responders were RTlC/RT1  c homozy- 
gotes.  That  the u haplotype was determining high-responsiveness was confirmed by 
the finding that (PVG ×  PVG-RTlU)F1  rats made high-titered anti-A  a responses, and 
that  in  a  (PVG  X  PVG-RTI=)F1  ×  PVG  baekcross  again  only  the  u/c  animals 
responded well.  There was no clear evidence  of Ir genes  in  the genetic  background 
either in the  (AO  ×  PVG)Fa  ×  PVG  backcross, or in  the response of four  (AUG  × 
PVG)Ft,  all of which were low responders  (AUG carries RTU on a  different  genetic 
background from PVG). 
We also studied the effect of including the RT11 (AGUS) haplotype in the responder BUTCHER,  CORVAL/~N, LICENCE, AND HOWARD  309 
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FIo. 3.  The genetics of responsiveness to RT1A  c. Accumulated data of primary, secondary, and 
tertiary lymphocytotoxic  tlters of sera from various rats immunized against PVG. All immunizations 
were congenic, the only genetic disparity between responder and immunogen being the RTIA  c 
region. Each symbol represents the response of one animal. 
Responder  Symbol  Genotype  Immunogen 
PVG.R1  0  rl/rl  c/c 
(PVG-RTI" X PVG.R1)Fa  []  a/r l  c/c 
(PVG-RTI  t X PVG.R l)Fl  •  l/rl  c/c 
(PVG-RTI  u X PVG.R 1)F]  •  u/rl  c/c 
Secondary immunizations were performed 21 or 25 d after the primary, and tertiary immunizations 45, or 
46 d after the primary. All bleeds were taken 7 d after the appropriate immunization. All antisera were 
titrated against lymph node cells from PVG donors. The symbols >  and <  indicate that the titer of the 
antiserum was greater than, or less than, that plotted. See Materials and Methods for definition of titer in 
these assays. 
genome. Progeny of an [l(AGUS)/c]  ×  c backcross were immunized against A a and 
the l(AGUS)/c heterozygous progeny were found to respond better than the c/c rats. 
When comparing the responses of l(AGUS)/c rats with those of u/c rats, however, it 
was clear that  the former made significantly weaker responses than the  latter  (Fig. 
2B). 
Fig. 3 shows results of the analysis of responsiveness to RT 1A  c. PVG.R 1 responded 
poorly to  PVG.  Inclusion of the RT1  = or RTlt(AGUS)  haplotype in the  responder 
produced  high  responsiveness. The  (PVG-RT1 ~ ×  PVG.R1)Fa  however,  was  a  low 
responder to PVG. Since all the animals involved in these experiments were congenic 
on the PVG background, we again conclude that the MHC of the responder governs 
the level of the response. 
Is High Responsiveness to RT1A a or RT1A ~ a Consequence of  a Strong Graft-vs.-Host Reaction 
(GVHR)?  The data in Figs. 2 and 3 are consistent with MHC-linked Ir gene-eontrol 
of  the  responses  to  the  RT1A  a  antigen,  different  haplotypes  determining  high, 
intermediate, or low responsiveness. It is apparent however that differential allogeneic 
effects could have influenced the results in some of the immunizations described. For 
example,  when  PVG.R1  (Aa/F)  or  (PVG.R1  ×  PVG)F1  (A~B~/ACB  ~)  lymphocytes 
were  used  as  immunogen in  PVG  (A¢/F)  or  (PVG  X  PVG-RTlU)F1  (AUB~/A"B  x) 
recipients,  the  injected  cells  could  have  made  a  GVHR  against  the  A u  and  B u 
alloantigens of the high responder, which are absent from  the low responder.  (The 310  /r GENE CONTROL OF  RESPONSES TO ALLOANTIGENS 
RT1B region encodes the strong GVHR-stimulating determinants of the rat  [11].)  It 
was possible that this GVHR caused a positive allogeneic effect in the high responder, 
leading to a high antibody response to the immunizing alloantigen RT1A a. A similar 
situation  could  also  arise  in  the  immunization  of (PVG.R1  ×  PVG-RTlU)F1  with 
PVG lymphoid cells. 
To control for this possibility, high- and low-responder animals were immunized in 
combinations in which allogeneic effects were equalized  (Table II). The responses of 
the  low-responder  PVG  against  PVG.R1  lymphoid  cells  were  compared  with  the 
responses  of  the  high-responder  (PVG  X  PVG.RTlU)F1  against  (PVG.R1  x 
PVG.RTlU)Fa lymphoid cells. Appropriate immunizations were also compared in the 
response  against  RT1A  e alloantigens.  In  both  these  cases,  the  residual  allogeneic 
effects are limited to the response of the immunizing cells to the A region alloantigens 
of one  haplotype of the  recipient,  that  is,  to  RT1A  c in  the  case  of immunization 
against RT1A  a, and to RT1A  a in the case of immunization against RT1A  c. Table II 
shows that the distinction between high and low responders was maintained in both 
immunizations in the absence of a major alloreaction against B region products. This 
experiment  suggests,  therefore,  that  the  immune  response  difference  is  correctly 
described in terms of Ir genes in the responder. It is of interest to note, however, that 
the response of (PVG X PVG.RTI")F1 to PVG.RI appeared slightly but consistently 
stronger than the response to (PVG.R1  X PVG.RTIU)F1 leaving open the possibility 
that an allogeneic effect may contribute in part to the magnitude of the high response. 
In the same context, however, the immunization (PVG-RT1 ~ X PVG.R1)F1 anti-PVG 
is a typical low-response combination (Fig. 3), despite the possibility of a full haplotype 
GVHR  (anti-AaB  ")  by the  immunizing inoculum  against  the  responder.  Finally,  it 
can  be seen  in  Table II (lines  iv and  viii)  that  even the  deliberate  inclusion  of an 
irrelevant full haplotype host-vs.-graft reaction in the responses PVG anti-(PVG.R1 
X PVG-RTI~)F1 and PVG.R1 anti-(PVG X PVG-RTI")Fx did not produce consistent 
high  responsiveness,  although  the  primary response  in  the  latter  combination  was 
much increased.  Further evidence that allogeneic effects are not  responsible for our 
observations is provided in the next section. 
From the results of the experiments described so far, we conclude that the differ- 
ential responsiveness of rat strains to RT 1A" and RT 1A  c alloantigens is due to MHC- 
linked/r-genes. We shall refer to these Ir genes as Ir-RTIA a and Ir-RT1A c, respectively. 
Does Ir  Gene Complementation Contribute to  High  Responsiveness in  Ir-RTIA~?  The 
previous experiments established that differential responsiveness to RT 1A" and RT 1A  c 
alloantigens was controlled by MHC-linked Ir genes in the responder. They did not, 
however, enable us to distinguish between dominant high responsiveness and Ir-gene 
complementation because all high-responder animals tested were heterozygotes at the 
MHC.  To  resolve  this  question  without  introducing  the  complication  of further 
allogeneic effects, we first assayed the primary responsiveness of c ~  (c  ×  u)F1  and 
u --*  (c  ×  u)F1  radiation chimeras to the RT1A" alloantigens of (PVG.R1  ×  PVG- 
RTI")F1 lymphoid cells.  This immunization  presents  a  single haplotype A ~ incom- 
patibility to both groups of chimeras, and minimizes graft vs. host (GVH) differences 
to a  single A c incompatibility  in  the  c ~  (c  ×  u)Fx  group  (assuming  any relevant 
GVH to be limited to the lymphomyeloid target from the fetal liver donor. The A c 
antigens will, of course, be present in the nonlymphoid compartment of both groups T
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of chimeras).  Four  u ~  (c  ×  u)Fa  chimeras  responded  very well,  whereas  seven c 
(c  ×  u)F1 chimeras were virtually unresponsive  (Fig. 4A). 
In  a  second  experiment,  we  attempted  to  avoid  allogeneic  effects  altogether  by 
immunizing  the  chimeras  with  heat-killed  and  homogenized  PVG-RT1  a  lymphoid 
cells.  Two  u  ~  (c  ×  u)F1  chimeras  produced  large  secondary  responses  to  RT1A a 
whereas two c---,  (c  x  u)Fa chimeras remained  unresponsive  (Fig.  4 B). 
Recently,  a  new MHC  recombinant  haplotype  r8 (A~B  ~)  was discovered  (23)  with 
which a  conventional test of the response of the u haplotype  to A a could be carried out 
in the absence of a  B-region disparity.  PVG-RTI",  (PVG  ×  PVG-RTI")F1,  and  PVG 
rats were immunized  with lymphoid  cells from R8  (a noninbred  line homozygous  for 
the r8 haplotype,  see Table  I)  and  the secondary  responses  to  RT1A"  analyzed.  In 
Table III, it can be seen that the former two types of rat made  good responses, whereas 
the  PVG  responded  poorly despite,  in  their case,  an  anti-B  ~ disparity  in  the  immu- 
A  B 
o 
1  antl-(PVG.~T..~U.PVGR1  jF  t  2  °:  anti-heat-killed  PVG-RT1  a 
~o 
c~(c xu)  ~  \ 
TWOFOLD  DILUTIONS  OF 
'  ,  ,  ,  , 
Vv 
ANTISERUM 
FIG.  4.  Antibody responses  of c ~  (c  ×  u)  and u ---, (c  x  u)  chimeras against  RTIA  a.  (A)  A 
primary response:  -8 mo after their reconstitution with parental fetal liver cells, seven c ~  (c ×  u) 
and four u ~  (c  ×  u) chimeras were immunized with live (PVG.R1  y  PVG-RTI")F1 spleen and 
lymph node cells. Bleeds were taken 11 d later and sera assayed on PVG.R1 targets. (B) A secondary 
response:  ~7 mo after their reconstitution with parental fetal liver cells, two c -", (c ×  u) and two 
u ----, (c  x  u) chimeras were immunized with heat-killed and homogenized PVG-RTI  a lymphoid 
cells. 33 d later, they were immunized in the same way, and after 7 d they were bled for serum. The 
sera  were  assayed  on  PVG.RI  targets.  Complement-dependent  lymphocytotoxicity  tests  were 
performed as described in Materials and Methods. The final concentration of antiserum in the first 
well of each titration was  1/6. 
TABLE  III 
Use of the R8 Strain to Demonstrate  that RTI u per se Is a 
High-responder  Haplotype 
Secondary serum lym- 
Responding strain  [mmunogen  phocytotoxic titer 
PVG  R8 (A"B")  34, 96,  136 
PVG-RTI  u  R8 (A"B  ~)  1,536, 1,536, 1,536 
(PVG ×  PVG-RTI")FL  R8 (AaB  ~)  543,  1,086, 1,536 
Three animals in each group were immunized s.c. and i.p. on days 0 and 27 
with 1/6 of a donor pool of R8 spleen and lymph node cells. They were bled 
for serum on day 34 and assayed against PVG.R1 lymphocytes. BUTCHER,  CORVALAN,  LICENCE,  AND  HOWARD  313 
nization. This experiment, therefore, confirms that the u haplotype, in its own right, 
confers high responsiveness to RT1A  a. 
Ir-RT1A a  Controls  the  Response  to  Two  Distinct  Epitopes  on  the  Same  Molecules.  Our 
earlier work has shown the presence of two topographically separated epitopes, P and 
S, on the RT1A  a molecules (14,  15). The P and S epitopes are defined by monoclonal 
antibodies, which we have used in two complementary assays to demonstrate that Ir- 
RTIA a  controls  the  level  of response  to  both  epitopes  concordantly.  In  the  first 
experiment, we assayed the ability of secondary immune sera from high-  and  low- 
responder  donors  to  compete  with  internally  labeled  monoclonal  antibodies  for 
binding to the  P  and  S sites of RT1A  ~ molecules on DA erythrocytes  (Fig.  5).  It is 
evident  that  antisera  from  high-responder  donors  had  a  much  higher  competitive 
inhibition titer for both monoclonal antibodies than antisera from low responders. 
Our second experiment excluded  the possibility that  the concordant  competitive 
inhibition  titers were a  result of the bulk of the antiserum being directed against an 
undefined site lying between P  and S and capable of inhibiting the binding of both 
P- and S-directed monoclonal antibodies. To do this, we exploited the phenomenon 
100. 
.L  ~  s0. 
so: 
~  . 
C  40• 
.0  . 
~  20. 
"~  o. 
~  _~: 
3H-R~/~ 
"~G  anti PVG.R1  ~,,,,~n~G.  R1 
1/4  f  '  f  '  i  i  ,  ,  I  , 
SERIAL TWOFOLD DILUTIONS OF ANTISERUM 
100. 
.~  8o: 
60: 
"~  40: 
8 
20: 
-  o 
-20 
3H-R~3 
.  _  . pVG.RT1  u- 
1 )4  '  '  i  ,  ,  ,  ,  ,  ,  , 
SERIAL TWOFOLD DILUTIONS OF ANTISERUM 
FiG.  5.  Inhibition  by  antisera  from  high-  and  low-responder rats  of the  binding of internally 
labeled monoclonal antibodies to two different epitopes of RT1A  a molecules. The antibodies used 
were [3H]Lys-R2/15S, which binds to the S site of RT1A  a and [3H]Lys-R3/13, which binds to the 
P site  (15).  The antisera were from secondary bleeds from the three  PVG rats and from the two 
PVG-RTIU/RTI  c (N7)  heterozygotes plotted on Figure 2 A. The assay was conducted as described 
in Materials and Methods• The final antiserum concentration in the first  well of each titration was 
1/4.  0% inhibition was defined from the counts in wells where medium was substituted for serum. 
The failure of inhibition of binding to reach 100% in B is attributed to a nonspecific component of 
binding present in the [aH]Lys-R3/13 preparation used. 314  Ir GENE CONTROL  OF RESPONSES TO ALLOANTIGENS 
of "synergistic lysis"  (15)  in  the  development of anti-RT1A  a  alIo-PFC  (18).  Anti- 
RT1A  a allo-PFC from a hyperimmune spleen do not form plaques on DA erythrocyte 
targets  because the  lytic efficiency of single monoclonal IgG alloantibodies is  low. 
However, if an excess of a  monoclonal anti-RT1A  a antibody is added exogenously to 
the Cunningham plaque chamber, large numbers of plaques are seen. The rationale 
for  this  synergistic effect  is  that  when  two  monoclonal IgG antibodies are  bound 
noncompetitively to two different epitopes of a single molecule, activation of comple- 
ment is extremely efficient. In the case of development of allo-PFC, one of the two 
antibodies is added exogenously, and the other is contributed by the PFC. Table IV 
shows the secondary anti-RT1A" PFC responses of seven (PVG  ×  PVG-RTlU)F1  × 
PVG backcross progeny typed for their possession of the RT1 u haplotype. It is clear 
that Ir-RT1A a controls the size of the PFC responses that are synergistic with both the 
anti-P and anti-S antibodies. Because the phenomenon of synergistic lysis depends on 
noncompetition between the two antibody components, it is clear from this and the 
competitive inhibition assay that Ir-RT1A a must control the immune response to two 
distinct determinants on the same molecule. 
Origin  of Anti-RT1A a  PFC in  c  +  u  ~  (c  ×  u)F1  Radiation  Chimeras.  Our  next 
experiment  showed  that  Ir-RTIA ~  probably  acts  at  the  level  of T  lymphocyte-B 
lymphocyte collaboration. Using cytotoxic alloantisera and complement, we analyzed 
the origin of anti-RT1A  a allo-PFC in fully reconstituted double parental fetal liver 
radiation chimeras, where one parental donor was of low-responder (RT1 c)  and the 
other of high-responder (R T1 u) genotype. To demonstrate chimerism in the population 
of PFC precursors, we also analyzed PFC secreting antibody to an antigen, SRBC, to 
which the response is not under/r  gene control. Table V  shows that >90% of anti- 
RT1A  a allo-PFC were of high-responder (RT1 u) origin, whereas anti-SRBC PFC were 
TABLE IV 
Secondary Spleen AUo-PFC Responses of (PVG X  PVG-RT1 u)  X  PVG Backcross Progeny to RTIA" 
Animal  RTI u 
Numbers of PFC per spleen 
in presence of* 
No addi- 
tional anti- 
body 
R2/lOP  R3/47 
Controls 
(AO × PVG)F1 unimmunized  +  36 (0.2)  144 (0.8)  72 (0.4) 
(AO × PVG)F1 No. 1  +  950 (5)  26,600  (140)  3,800  (20) 
(AO × PVG)F1 No. 2  +  309 (1.6)  31,800  (165)  5,790  (30) 
(PVG-RTI u × PVG) × PVG backcross progeny 
Serial No. 2  -  403 (1.8)  1,120 (5)  179 (0.8) 
No. 11  -  96 (0.6)  96 (0.6)  32 (0.2) 
No. 12  -  63 (0.4)  94 (0.6)  63 (0.4) 
No. 3  +  1,080 (5)  25,800  (120)  4,300  (20) 
No. 4  +  1,160 (5)  36,000  (155)  4,640  (20) 
No. 13  +  203 (1.4)  7,980 (55)  1,450 (10) 
Animals were immunized by the  following schedule: day  0,  l/5  donor per  recipient  (s.c. and i.p. 
injections);  day 8, primary bleed; day 33, 1/5 donor per recipient (i.v.); day 40, rats killed for spleen PFC 
analysis. Immunizing spleen and lymph node cells  came from N9 or N 10 PVG-RTIrl/RTIC heterozygotes. 
* Details of the plaquing techique are given in Materials and Methods. The figures in parentheses are the 
numbers of PFC per 10  n spleen cells. BUTCHER,  CORVAL,~N,  LICENCE,  AND  HOWARD  315 
TABLE  V 
Responder Origin of Anti-RTIA a PFC in Tetraparental Radiation  Chimeras [c +  u ~  (c  ×  u)F1] 
Serum treatment 
Percent 
spleen cells 
dead 
Number of plaques per spleen vs. 
DA RBC (percent  SRBC (percent 
reduction of control)  reduction of control) 
Rat  l 
NRS +  complement (C')  ND*  20,500 (control)  69,500 (control) 
anti-RT1 ~ +  C'  39.6  1,750  (91.4)  29,000 (58.3) 
anti-RTl e +  C'  39.4  19,500 (4.8)  44,000 (36.7) 
anti-RTl u +  anti-RT1 c +  C'  76.8  1,875  (90.8)  4,700 (93.2) 
Rat 2 
NRS +  C'  ND  775 (control)  61,500 (control) 
anti-RT1 u +  C'  37.3  <25 (96.8)  25,500 (58.5) 
anti-RTl c +  C'  40.6  625 (19,4)  41,500 (32.5) 
anti-RT1  u +  anti-RT1  c +  C'  73.6  <25 (96.8)  5,350 (91.3) 
This  table  shows  that  essentially  all  the  PFC  making  antibody  against  RTIAa-S  epitopes  in 
c +  u --* (c  ×  u~Fl chimeras are of u (high-responder) origin. The PFC simultaneously developed against 
SRBC are of both c and u origin, demonstrating the chimeric state of the population of antibody-forming 
cell precursors. 
The chimeras were immunized with (PVG.R1  ×  PVG-RTI")F1  spleen and lymph node cells (22  ×  106 
cells s.c. and i.p.)  42 d  after reconstitution, and boosted  18 d  later with  108 (PVG.R1  ×  PVG-RTIU)F1 
lymphoid cells and  1 ml  1% SRBC given i.v. in a  single injection. Spleens were removed 5 d  later for 
assay of PFC against DA RBC and SRBC as described in Materials and Methods. PFC against DA RBC 
were developed in the presence of the monoclonal alloantibody R2/10P.HL  (anti-RT 1Aa-P epitope). 
Before incubation with antisera, PFC were developed against both target erythrocytes. Chimera  1 gave 
83,000 PFC against DA and 301,000 against SRBC; chimera 2 gave 2,500 PFC against DA and 231,000 
against  SRBC.  After incubation  with  normal  serum and complement as described  in  Materials  and 
Methods, between 23.1  and 31% of PFC were recovered against the two targets. Nonspecific loss of PFC 
during incubation with  antiserum and complement  has been  reported  elsewhere  (20).  Both chimeras 
were fully and approximately equally reconstituted with the two parental populations, assayed by Trypan 
Blue dye exclusion on spleen celt suspensions after the plaque assay and confirmed by the origin of anti- 
SRBC PFC. 
* Not determined. 
approximately one-third of RT1 c origin and two-thirds of RT1 u origin. Although  the 
anti-SRBC  response was similar in  magnitude  in  both  chimeras  assayed, the  anti- 
RT1A  a responses were very different,  for unknown  reasons.  Interestingly, however, 
even  the  very  small  anti-RT1A  a  response  of the  poorer  responder  was  essentially 
exclusively mediated  by RTI"  cells.  The  limitations  of the experimental  technique 
would not allow us to identify a  very small  (<10%)  RTlC-derived component in the 
anti-RT 1A  ~ response of either chimera. 
Discussion 
This paper deals with the mechanisms that control antibody responses to the class 
I  (mouse  H-2K/D-like)  major  alloantigens  of the  rat.  We  have  found  that  these 
responses are under  potent,  MHC-linked Ir-gene control.  In general,  immunization 
with viable allogeneic cells raises technical problems of interpretation because of the 
possible intervention of allogeneic effects, mediated by immunogen against responder 
or  vice  versa,  in  modulating  response  magnitude.  A  major  part  of this  study  is 316  Ir GENE CONTROL OF  RESPONSES TO ALLOANTIGENS 
therefore devoted to showing that although  allogeneic effects may indeed  influence 
response magnitude,  particularly in tending to raise the response of low responders, 
they are unable to override the Ir-gene effects. Since the immune response measured 
was against the class I alloantigens, it was possible in appropriate strain combinations 
to minimize allogeneic effects in high- and low-responder combinations using viable 
immunogens (Table II). Finally, it was possible to show that heat-killed and homog- 
enized  allogeneic cells would  immunize  high  responders  and  fail  to  immunize  low 
responders. 
It is known from primary amino acid sequence  (24)  and from sequential  precipi- 
tation studies that the A region of R Tla specifies at least two class I molecules. We are 
not at present in a  position to say whether Ir-RTIA ~ controls the antibody response 
to  epitopes  on  both  molecules.  Certainly,  our  results  are  compatible  with  this 
interpretation.  The alternative possibility is that the differential responsiveness con- 
trolled by Ir-RTIA ~ applied to only one of the RT 1A" molecules, whereas both R TIC 
and RT1 ~ are low responders to the second molecule. The possibility that response to 
both  RT1A"  molecules  is  controlled  concordantly  because  of  a  high  degree  of 
structural  similarity  between  the  two  class  I  products  of the  RT1 ~  haplotype  is 
presently under investigation. 
The properties of the Ir genes uncovered in this study are conventional in several 
respects. The haplotype RTlC determines the low-response phenotype in the response 
to  RT1A  ~,  whereas  RT1 u  determines  dominant  high  responsiveness.  Similarly,  the 
haplotype  RT1 rl  determines  low  responsiveness  to  RT1A  c,  whereas  again  RTI" 
determines dominant  high  responsiveness. There is apparently no trans-complemen- 
tation  involved in  the  response to  RT1A  ~ among the  alleles  that  we have studied. 
Second,  Ir-RTIA ~ controls concordantly the antibody response to two independent 
epitopes on the RT1A" molecule, a result strictly analogous to the concordant control 
of antibody responses to poly(L-Tyr, i~-Glu)-D,l.-Ala--L-Lys (T,G-A--L) determinants 
and  to  dinitrophenyl  (DNP)  on  the  immunogen  DNP-T,G-A--L  (25).  Third,  in 
tetraparental  radiation chimeras, the alloantibody against  RT1A" was made exclu- 
sively by PFC of high-responder origin, again in strict conformity with the findings of 
Press  and  McDevitt  (26)  in  the  response  of  mice  to  T,G-A--L.  In  view  of  the 
demonstrated T  cell dependence of alloantibody responses in mice and rats (27,  28) 
and the absence of a B cell defect in our low-responder strain (Fig.  1) we feel entitled 
to  conclude  that  the  Ir  gene  controlling  the  response  to  the  RT1A"  molecules 
determines the specificity with which T  cell help is delivered to the B cell. 
Because of the nature of the antigenic molecules involved in these experiments, this 
result  is  of some  interest.  It  is  now  impossible  not  to  consider  that  MHC-linked 
immune responses genes of a conventional type reflect an aspect of MHC restriction 
in the helper-cell compartment. The difference between low and high responsiveness 
in  conventional  systems is  undoubtedly  a  function  of the different  consequences  of 
presentation  of  the  immunizing  antigen  in  association  with  the  low-  and  high- 
responder MHC allelic products. Because the Ir gene effects in the response to RT 1A" 
antigens are essentially independent of the form of delivery of the antigen, we conclude 
that  these transmembrane molecules, even when  delivered  on  viable cells, must  be 
processed by the recipient  and ultimately presented  to the immune system on host 
antigen-presenting cells. In other words, the native membrane context of the immu- 
nizing  alloantigens  becomes  irrelevant  to  the  outcome  of  the  immunization:  the BUTCHER, CORVALAN, LICENCE, AND HOWARD  317 
immunizing form is determined exclusively by the host. This conclusion is similar to 
that  proposed by Matzinger and  Bevan  (29)  and by Korngold and  Sprent  (30)  for 
MHC-restricted  cytotoxic  responses  to  minor  transplantation  antigens,  and  more 
recently by Weinberger et al.  (31)  in a  study of the conditions required for immuni- 
zation of in vitro cultures with the mouse class I alloantigen  H-2K  k associated with 
lipid vesicles. In these last experiments, although the readout was anti-H-2K  k cytotoxic 
responses, the authors concluded that H-2K  k molecules were presented to helper cells 
in the system by an Ia-bearing presenting cell. 
Our experiments by no means exclude the possibility that class I alloantigens can 
immunize for help in their native configuration on viable donor cells. For example, in 
the immunization of PVG-RTI" against PVG.R8, the viable immunogen carries the 
RT1A  a molecule as well as the RTIB" product, which we assume to be the relevant 
determinant for high responsiveness by analogy with other Ir genes in the rat (7).  We 
cannot tell in this case whether the response seen is a result of antigen handling by the 
host or of direct presentation by the donor cells. It is unfortunate that this issue may 
not  be easy to resolve because it  would  be interesting  to know whether  the  native 
configuration  of a  transmembrane  molecule capable of forming its own restricting 
interactions could be the same as the processed configuration in which the molecule 
is itself restricted by another membrane component. 
It is worth remarking that the failure of PFC of low-responder origin to participate 
in the antibody response to RT1A  a is another clear example where MHC restriction 
imposed on a  helper cell population at the antigen-presentation stage is also visited 
on  the  B  cells at  the effector stage of the  response.  The conservation  of helper cell 
restriction specificity from induction to effect has now been observed in three antibody 
responses under Ir gene control (26, 32; and this study) and in experimentally biased 
responses to erythrocyte antigens in vivo (33)  and in vitro (34). Why restriction at the 
level of induction  of the B cell apparently fails in other experimental protocols (35- 
37)  is still unexplained and will presumably remain so until the molecular basis of T- 
B interaction in linked-recognition systems is further clarified. 
The properties of the antibody response to class I transplantation antigens described 
in this paper suggest that the serologically defined epitopes P and S on RT1A  ~ behave 
like structurally and topographically distinct  haptens on a  molecule with undefined 
carrier determinants. Similar considerations apply to the RT1A  c product, although in 
this case, distinct  haptenic groups have not yet been defined.  In view of the obvious 
antigenic complexity of class I alloantigens, it is interesting that Ir gene control of the 
response  to  these  molecules  should  be  so  clear-cut  and  easy  to  demonstrate.  The 
implication is that at least one regulatory component in the response has a  range of 
specificity considerably narrower than the total antigenic complexity of the molecule. 
It is possible that  there is only one effective carrier epitope on the class I molecules, 
and that failure to recognize this epitope is the cause of low responsiveness. Alterna- 
tively, the antigens may present a  multiplicity of carrier epitopes to both high-, and 
low-responder  strains,  and  Ir  gene  control  may  be  through  the  presentation  of a 
suppressor  epitope  in  low-responder  strains.  The  clearest  precedent  for  a  simple- 
suppressor model oflr gene control over complex molecules comes from the properties 
of the  N-C  determinant  of lysozyme, which  induces  a  suppressive response in  low- 
responder mice that can override help through other carrier determinants (38).  In this 318  Ir GENE CONTROL OF  RESPONSES TO  ALLOANTIGENS 
case,  the  MHC  linkage  of  the  lr  gene  apparently  results  from  MHC-restricted 
recognition of the suppression epitope in the low-responder strain  (39, 40). 
The experiments described in this paper identify a  conventional mechanism of T 
cell-mediated  help  for antibody responses  to  a  major  transplantation  antigen.  We 
shall  show  2 that  apparently  similar  Ir  gene  control  exists  for  the  rejection  of skin 
allografts  bearing  the  same  major  antigens  and  for  the  development  of specific 
cytotoxic T  cell  function in vivo. These experiments suggest that  the Ir gene defect 
extends its influence to several modalities of the immune response, but in all cases, we 
are inclined to localize the primary defect to antigenic recognition required  for the 
delivery of specific help to effector-cell precursors, rather than to the effector modalities 
themselves. 
Summary 
We have identified  two major histocompatibility complex (MHC)-linked Ir genes 
that control the antibody responses made by rats against class I  major alloantigens. 
We  have  named  these  genes  Ir-RT1A ~  and  Ir-RT1A c.  These  Ir  genes  determine 
responsiveness of the immunized animal in a typical codominant fashion. There is no 
evidence so far for trans-complementation between low-responder haplotypes. Detailed 
studies  of Ir-RT1A ~  indicate  that  it  controls the  antibody response  to  at  least  two 
distinct alloantigenic determinants on RT1A  a molecules. These class I molecules thus 
behave like  hapten-carrier conjugates when the response against the carrier is under 
Ir gene control. Analysis of the origin of alloantibody-forming cells  in tetraparental 
radiation  chimeras  indicates  that  Ir-RT1A ~  must  control  the  provision  of effective 
help to B cells.  In many respects,  therefore, the properties of Ir-RT1A ~ are broadly 
similar to those described for Ir genes controlling antibody responses to conventional 
antigens. The existence of apparently conventional Ir genes controlling the antibody 
response to major alloantigens strongly suggests that the processing of these transmem- 
brane molecules by host antigen-presenting cells  is a  prerequisite for immune induc- 
tion,  and  that  it  is  the  MHC of the  responder rather  than  that  of the  allograft  to 
which T  helper cells  are restricted in alloimmune responses in vivo. 
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